A woman in her 60s was diagnosed with high-grade leiomyosarcoma of the uterus in 2017 for which she underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. In 2020, she relapsed in the liver and spine. In November 2020, she underwent posterior lateral stabilization of C7-T4 for a T2 vertebral body metastasis causing cord compression, followed by postoperative stereotactic body radiation therapy to T2 to T3 (35 Gy/5 fractions) in January 2021. In February 2021, she received palliative radiation therapy (20 Gy/5 fractions) to T9 to T12 for a T11 vertebral body metastasis with epidural extension. From January to August 2021, she was treated with gemcitabine, and in September 2021, she received her first dose of liposomal doxorubicin. Two weeks later, she developed progressive bilateral lower extremity numbness, pain, weakness, and imbalance, prompting emergent evaluation. Magnetic resonance imaging (MRI) findings demonstrated extensive spinal cord edema extending from T2 to the conus and a posterior ring-enhancing intramedullary lesion at T9 to T10 without any mass effect (Figure 1). Because the intramedullary lesion appeared atypical for malignant disease given the lack of mass effect, she was prescribed high-dose steroids while further workup was pursued. Lumbar puncture showed no malignant cells. Positron emission tomographic-computed tomographic (PET/CT) scan demonstrated multifocal intensely F-fluorodeoxyglucose (FDG)-avid disease, but only mild uptake from T9 to T12 and no definitive FDG-avidity at the intramedullary lesion. Her symptoms remained stable with steroid treatment and a plan was made to repeat an MRI of the spine in 6 to 8 weeks.
Lamba N, Bitterman DS. An Intramedullary Enigma. JAMA Oncol. 2022;8(5):770–771. doi:10.1001/jamaoncol.2022.0462
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.